Immunostimulatory polynucleotide/immunomodulatory molecule conjugates

a technology of immunomodulatory molecule and immunonucleotide, which is applied in the field of immunonucleotide/immunomodulatory molecule conjugates, can solve the problems of general absence or weakness

Inactive Publication Date: 2003-12-18
CARSON DENNIS A +2
View PDF23 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] Specifically, the ISS-PN and IMM components of the ISS-PN / IMM conjugates synergistically boost the magnitude of the host immune response against an antigen to a level greater than the host immune response to either the IMM, antigen or ISS-PN alone. The ISS-PN / IMM conjugates also shift the host cellular immune response away from the helper T lymphocyte type 2 (Th2) phenotype toward a helper T lymphocyte type 1 (Th1) phenotype. These responses to ISS-PN / IMM conjugates are particularly acute during the important early phase of the host immune response to an antigen.
[0008] To these ends, ISS-PN / IMM conjugates are delivered by any route through which antigen-sensitized host tissues will be contacted with the ISS-PN / IMM conjugate. ISS-PN / IMM conjugates administered in this fashion boost both humoral (antibody) and cellular (Th1 type) immune responses of the host. Thus, use of the method to boost the immune responsiveness of a host to subsequent challenge by a sensitizing antigen without immunization avoids the risk of Th2-mediated, immunization-induced anaphylaxis by suppressing IgE production in response to the antigen challenge. An especially advantageous use for this aspect of the invention is treatment of localized allergic responses in target tissues where the allergens enter the body, such as the skin and mucosa.
[0010] The shift to a Th1 phenotype achieved according to the invention is accompanied by increased secretion of IFN .alpha., .beta. and .gamma., as well as IL-12 and IL-18. Each of these cytokines enhance the host's immune defenses against intracellular pathogens, such as viruses. Thus, the invention encompasses delivery of ISS-PN / IMM conjugates to a host to combat pathogenic infection.

Problems solved by technology

While most current vaccines elicit reasonable antibody responses, cellular responses (in particular, major histocompatibility complex (MHC) class I-restricted cytotoxic T cells) are generally absent or weak.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
  • Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
  • Immunostimulatory polynucleotide/immunomodulatory molecule conjugates

Examples

Experimental program
Comparison scheme
Effect test

example ii

[0142] Suppression of IgE Antibody Response to Antigen by Immunization with ISS-PN / IMM

[0143] To demonstrate the IgE suppression achieved through stimulation of a Th1 type cellular immune response in preference to a Th2 type cellular immune response, five to eight week old Balb / c mice were immunized with AgE as described in the previous Example.

[0144] IgE anti-Age were detected using a solid phase radioimmunoassay (RAST) in a 96 well polyvinyl plate (a radioisotopic modification of the ELISA procedure described in Coligan, "Current Protocols In Immunology", Unit 7.12.4, Vol. 1, Wiley & Sons, 1994), except that purified polyclonal goat antibodies specific for mouse e chains were used in lieu of antibodies specific for human Fab. To detect anti-AgE IgE, the plates were coated with AgE (10 .mu.g / ml). The lowest IgE concentration measurable by the assay employed was 0.4 ng of IgE / ml.

[0145] Measuring specifically the anti-antigen response by each group of mice, as shown in FIG. 5, anti-Ag...

example iii

INF.gamma. Levels in Mice After Delivery of ISS-PN / IMM

[0147] BALB / c mice were immunized with .beta.gal as described in Example I then sacrificed 24 hrs later. Splenocytes were harvested from each mouse.

[0148] 96 well microtiter plates were coated with anti-CD3 antibody (Pharmingen, La Jolla, Calif.) at a concentration of 1 .mu.g / ml of saline. The anti-CD3 antibody stimulates T cells by delivering a chemical signal which mimicks the effects of binding to the T cell receptor (TCR) complex. The plates were washed and splenocytes added to each well (4.times.10.sup.5 / well) in a medium of RPMI 1640 with 10% fetal calf serum. Supernatants were obtained at days 1, 2 and 3.

[0149] Th1 cytokine (INF.gamma.) levels were assayed with an anti-INF.gamma. murine antibody assay (see, e.g., Coligan, "Current Protocols in Immunology", Unit 6.9.5., Vol. 1, Wiley & Sons, 1994). Relatively low levels of INF-.gamma. would be expected in mice with a Th2 phenotype, while relatively high levels of INF-.gamma...

example iv

Boosting of CTL Responses by ISS-PN / IMM

[0151] A mixture of lymphoytes was obtained and contacted with .beta.gal antigen alone or as part of the constructs and mixtures described in Example I. As shown in FIG. 6, CTL production in response to ISS-PN / IMM was consistently higher than the response to antigen delivered in other forms; even twice as high than in animals treated with an unconjugated mixture of ISS-PN and IMM antigen.

[0152] In the experiment, the higher values for the mice treated with M-ISS-PN / IMM after antigen challenge as compared to the conventionally immunized mice is most likely owing to the antigen carrier properties of DY1019.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
frequencyaaaaaaaaaa
Structureaaaaaaaaaa
Login to view more

Abstract

Immunostimulatory polynucleotide-immunomodulatory molecule conjugate compositions are disclosed, These compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the conjugate includes at least one immunostimulatory oligonucleotide nucleotide sequence (ISS). Methods of modulating an immune response upon administration of the polynucleotide-immunomodulatory conjugate preparation to a vertebrate host are also disclosed.

Description

[0001] This is a continuation-in-part and utility conversion of U.S. Provisional Patent Application Serial No. 60 / 028,118, filed Oct. 11, 1996.[0003] The invention relates to compositions comprising an immunomodulatory molecule (IMM) including an antigen, conjugated to a polynucleotide that contains or consists of at least one immunostimulatory oligonucleotide (ISS-PN). It also relates to methods for modulating the immune response of a vertebrate host to an antigen.HISTORY OF THE RELATED ART[0004] Conventionally, immunization of a host against an antigen is accomplished by repeatedly vaccinating the host with the antigen. While most current vaccines elicit reasonable antibody responses, cellular responses (in particular, major histocompatibility complex (MHC) class I-restricted cytotoxic T cells) are generally absent or weak. For many infectious diseases, such as tuberculosis and malaria, humoral responses are of little protective value against infection.[0005] Given the weak cellul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7088C12N15/09A61K38/00A61K39/00A61K39/36A61K39/385A61K47/48A61P37/02C12N15/117
CPCA61K38/00A61K39/36A61K39/385A61K47/48023A61K2039/55516A61K2039/55522C12N2310/3513A61K2039/57A61K2039/6025C12N15/117C12N2310/17C12N2310/313C12N2310/315A61K2039/55561A61K47/54A61P37/02A61P37/06Y02A50/30
Inventor CARSON, DENNIS A.RAZ, EYALROMAN, MARK
Owner CARSON DENNIS A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap